^
    Back
    Association details:
    Biomarker:FGFR1 amplification
    Cancer:Gastric Cancer
    Drug:fexagratinib (ABSK091) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

    Excerpt:
    ...- In the expansion for the study patients must have a tumour at least 1cm in size that can be measure using a CT or MRI scan, and provide a tumour sample to the sponsor company for testing of FGFR1 and/or 2 amplification...
    Trial ID:
    NCT00979134
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours

    Excerpt:
    ...- FGFR1 amplification Advanced squamous cell lung cancer...
    Trial ID:
    NCT01795768
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A study of AZD4547 in patients with tumours having high number of copies of the FGFR1 or FGFR2 gene.

    Excerpt:
    ...― FGFR1 or FGFR2 amplification as assessed by AZ approved laboratory. ...
    Trial ID:
    2011-003718-18
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.

    Excerpt:
    This is a phase II Simon 2 stage design for patients (pts) with FGFR1 (HER2 negative breast/NSCLC) or FGFR2 (gastroesophageal) amplified tumors treated with AZD4547 80mg twice daily...Confirmed RR was 33% (3/9) in FGFR2 amplified GC, and 12.5% (1/8) FGFR1 amplified BC...
    DOI:
    10.1200/jco.2015.33.15_suppl.2508